Targeting a protein could be key to suppressing breast cancer metastasis

Targeting a protein could be key to suppressing breast cancer metastasis

Study shows protective cells reduce lung cancer risk in ex-smokers Xu and co-author Gaofeng Xiong analyzed DNA/RNA generated from human breast cancer tissue, which showed that increased production of Hsp47 was linked to metastasis in triple-negative breast cancer. About 10-20% of breast cancers are classified as triple-negative, which is considered to be more aggressive and have a poorer prognosis than other types of breast cancer . The results suggest that targeting Hsp47 could be a promising strategy to block cancer cell-platelet interaction and cancer colonization in secondary organs for triple-negative breast cancer patients, says Xu. If we can find a way to target this pathway with therapeutics we could block this process and therefore inhibit metastasis." Ren Xu, researcher, Markey Cancer Center, University of Kentucky Xu says another benefit of the study is the potential that Hsp47 could serve as a prognosis or biomarker of metastasis since it is often amplified in the genes of metastatic breast cancer tissue. The study was published in PNAS and was supported by funding from the National Cancer Institute. Source: Journal reference: Xiong, G., et al. (2020) Hsp47 promotes cancer metastasis by enhancing collagen-dependent cancer cell-platelet interaction. PNAS . doi.org/10.1073/pnas.1911951117 .



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More